{
  "ticker": "CLDX",
  "company_name": "Celldex Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05031624",
      "title": "A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Subjects",
      "start_date": "2021-08-30",
      "completion_date": "2022-01-14",
      "enrollment": 0,
      "sponsor": "Celldex Therapeutics"
    },
    {
      "nct_id": "NCT05774184",
      "title": "A Study of CDX-0159 in Patients With Eosinophilic Esophagitis",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Eosinophilic Esophagitis",
      "start_date": "2023-06-01",
      "completion_date": "2026-01",
      "enrollment": 0,
      "sponsor": "Celldex Therapeutics"
    },
    {
      "nct_id": "NCT03688178",
      "title": "DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Glioblastoma",
      "start_date": "2020-08-26",
      "completion_date": "2026-03",
      "enrollment": 0,
      "sponsor": "Annick Desjardins, MD"
    },
    {
      "nct_id": "NCT05349890",
      "title": "Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Malignant Epithelial Neoplasms",
      "start_date": "2023-04-03",
      "completion_date": "2028-04-15",
      "enrollment": 0,
      "sponsor": "Providence Health & Services"
    },
    {
      "nct_id": "NCT02302339",
      "title": "A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Melanoma",
      "start_date": "2014-11",
      "completion_date": "2018-10-03",
      "enrollment": 0,
      "sponsor": "Celldex Therapeutics"
    },
    {
      "nct_id": "NCT02543645",
      "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer",
      "start_date": "2015-10",
      "completion_date": "2017-05-22",
      "enrollment": 0,
      "sponsor": "Celldex Therapeutics"
    },
    {
      "nct_id": "NCT02413827",
      "title": "A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Unresectable Stage III or Stage IV Melanoma",
      "start_date": "2015-04",
      "completion_date": "2016-11-09",
      "enrollment": 0,
      "sponsor": "Celldex Therapeutics"
    },
    {
      "nct_id": "NCT00648102",
      "title": "Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer",
      "start_date": "2006-01",
      "completion_date": "2009-12",
      "enrollment": 0,
      "sponsor": "Celldex Therapeutics"
    },
    {
      "nct_id": "NCT02270372",
      "title": "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Advanced Breast Carcinoma, Advanced Ovarian Carcinoma",
      "start_date": "2014-11",
      "completion_date": "2016-06",
      "enrollment": 0,
      "sponsor": "Cascadian Therapeutics Inc."
    },
    {
      "nct_id": "NCT03617328",
      "title": "Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Melanoma",
      "start_date": "2018-11-13",
      "completion_date": "2024-01-19",
      "enrollment": 0,
      "sponsor": "Craig L Slingluff, Jr"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 23,
      "PHASE2": 14,
      "PHASE1, PHASE2": 8,
      "PHASE3": 4,
      "EARLY_PHASE1": 1
    },
    "by_status": {
      "COMPLETED": 27,
      "ACTIVE_NOT_RECRUITING": 4,
      "TERMINATED": 11,
      "RECRUITING": 7,
      "WITHDRAWN": 1
    },
    "active_trials": 11,
    "completed_trials": 27,
    "conditions": [
      "Advanced Breast Carcinoma, Advanced Ovarian Carcinoma",
      "Advanced Cancer",
      "Advanced Head and Neck Squamous Cell Carcinoma",
      "Advanced Malignancies",
      "Atopic Dermatitis",
      "Breast Cancer",
      "Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer",
      "Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer",
      "Chronic Inducible Urticaria",
      "Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism",
      "Chronic Spontaneous Urticaria",
      "Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism, Symptomatic Dermatographism, Cholinergic Urticaria",
      "Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II, C3 Glomerulonephritis",
      "Eosinophilic Esophagitis",
      "Glioblastoma",
      "Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component",
      "Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma",
      "Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed",
      "Healthy",
      "Healthy Participants",
      "Healthy Subjects",
      "Low-Grade B-cell Lymphoma",
      "Malignant Epithelial Neoplasms",
      "Malignant Glioma",
      "Melanoma",
      "Melanoma, Metastatic Melanoma",
      "Metastatic Castration-resistant Prostate Cancer",
      "Metastatic Pancreatic Adenocarcinoma",
      "Non Small Cell Lung Cancer, Lung Cancer",
      "Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors",
      "Oral Mucositis, Stomatitis",
      "Prostatic Neoplasms, Prostate Cancer",
      "Prurigo Nodularis",
      "Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms, Metastatic Renal Cell Carcinoma, Ovarian Clear Cell Carcinoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed",
      "Stomatitis",
      "Thyroid Cancer",
      "Triple Negative Breast Cancer",
      "Unresectable Stage III or Stage IV Melanoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:29.329685",
    "search_query": "Celldex Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Celldex+Therapeutics,+Inc."
  }
}